- In a national study of Medicare beneficiaries with disability and active opioid use disorder (OUD) symptoms, White patients received and filled prescriptions for medications to treat OUD up to 80% more frequently than Black patients and up to 25% more frequently than Hispanic patients in the six months following a high-risk OUD-related event such as an overdose or infection
- Across racial groups, patients visited health care providers a similar number of times in the six months post OUD event—indicating that disparities in treatment do not stem from disparities in seeking care
Embargoed for release: Wednesday, May 10, 2023, 5:00 PM EST
Boston, MA—In the wake of an opioid-related event such as an overdose, infection, or detox admission, White patients received medication for opioid use disorder (OUD) up to 80% more frequently than Black patients and up to 25% more frequently than Hispanic patients, according to a new study led by researchers at Harvard T.H. Chan School of Public Health. Across racial groups, patients made a similar number of visits to health care providers in the six months following such an event—indicating that disparities in treatment are not explained by low contact with care.
“Opioid overdoses are rising faster in the Black population than in any other racial group: In 2021, they surpassed overdose rates in the White population for the first time in decades. And rates of overdose in the Hispanic population have recently risen by 40%,” said lead author Michael Barnett, associate professor of health policy and management. “We need to understand barriers to obtaining life-saving addiction treatment for minority populations to address this huge demographic shift and public health crisis.”
The study will be published in the May 11, 2023 edition of the New England Journal of Medicine.
While racial disparities in addiction treatment have been identified by previous studies, little of this research examined the full range of medications for OUD or accounted for non-recommended medications like opioid analgesics and benzodiazepines, both of which are associated with substantial risk for OUD patients. To fill in these gaps, researchers pulled a random 40% sample of Medicare beneficiaries with disability—a group of Americans among the most affected by OUD—who experienced at least one acute OUD-related event between 2016 and 2019. Using the Medicare claims, researchers observed 25,904 OUD-related events—15.2% of which occurred among Black patients, 8.1% among Hispanic patients, and 76.7% among White patients.
In 180 days following these events, Black patients received and filled a prescription for buprenorphine, a lifesaving therapy for OUD, 12.7% of the time; Hispanic patients, 18.7% of the time; and White patients, 23.3% of the time. Naloxone, a drug for reversing overdoses that has few restrictions on its distribution (in contrast to buprenorphine), followed the same pattern: Black patients received and filled a prescription after 14.4% of OUD events; Hispanic patients, 20.7%; and White patients, 22.9%. In a follow-up analysis using data from 2020 to 2021, researchers found that these differences were not explained by differing access to methadone by racial/ethnic group. Black patients received and filled these prescriptions after 8.3% of OUD events; Hispanic patients after 11.2% of OUD events; and White patients after 8.6% of OUD events.
Despite well-known and substantial risks, prescriptions for opioid analgesics and benzodiazepines were received and filled frequently. Prescriptions for opioid analgesic were received and filled after 23% of OUD-related events regardless of race. But prescriptions for benzodiazepines were received and filled by Black patients 23.4% of the time, by Hispanic patients 29.6% of the time, and by White patients 37.1% of the time.
“Skyrocketing rates of overdoses in minority groups are unlikely to shift without a major overhaul in the addiction treatment system,” said Barnett. “Addressing the overdose crisis and racial disparities in addiction will likely require community-specific interventions that engage with minority populations and the clinicians who serve them to reduce stigma and bolster trust.”
Ellen Meara, professor of health economics and policy at Harvard Chan School, was a co-author.
Funding came from National Institute on Drug Abuse grants R01 DA049757, R01 DA048533, and P30 DA035772 and National Institute on Aging grant K23 AG058806.
“Racial inequality in receipt of medications for opioid use disorder,” Michael L. Barnett, Ellen Meara, Terri Lewinson, Brianna Hardy, Deanna Chyn, Moraa Onsando, Haiden A. Huskamp, Ateev Mehrotra, Nancy E. Morden, New England Journal of Medicine, May 11, 2023, doi: 10.1056/NEJMsa2212412
Visit the Harvard Chan School website for the latest news, press releases, and multimedia offerings.
Harvard T.H. Chan School of Public Health brings together dedicated experts from many disciplines to educate new generations of global health leaders and produce powerful ideas that improve the lives and health of people everywhere. As a community of leading scientists, educators, and students, we work together to take innovative ideas from the laboratory to people’s lives—not only making scientific breakthroughs, but also working to change individual behaviors, public policies, and health care practices. Each year, more than 400 faculty members at Harvard Chan School teach 1,000-plus full-time students from around the world and train thousands more through online and executive education courses. Founded in 1913 as the Harvard-MIT School of Health Officers, the School is recognized as America’s oldest professional training program in public health.
New England Journal of Medicine
Method of Research
Subject of Research
Racial inequality in receipt of medications for opioid use disorder
Article Publication Date